TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
Started April 1, 2019
338
Tolerability and Activity of Ublituximab, Umbralisib, and Ibrutinib in Patients with Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma: A Phase 1 Dose Escalation and Expansion Trial
Started February 1, 2019
279
Umbralisib in Combination with Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia or Mantle Cell Lymphoma: A Multicentre Phase 1–1b Study
Started December 14, 2018
327
Combination of Umbralisib, Ublituximab, and Bendamustine is Safe and Highly Active in Patients with Advanced DLBCL and Follicular Lymphoma
Started December 3, 2018
447
Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation
Started December 2, 2018
328
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Started June 16, 2018
294
Resurrecting response to ruxolitinib: A Phase I study of ruxolitinib and umbralisib (TGR-1202) in ruxolitinib-experienced myelofibrosis
Started June 16, 2018
396
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with CLL who are Intolerant to Prior BTK or PI3K Inhibitor Therapy
Started June 16, 2018
273
TG-1701 is a novel, orally available and covalently bound BTK inhibitor
Started June 15, 2018
419
Long Term Integrated Safety Analysis Of Umbralisib (TGR-1202), A PI3K?/Ck1? Inhibitor With A Differentiated Safety Profile, In Patients With Relapsed/Refractory Lymphoid Malignancies
Started June 15, 2018
261
TG-1601 is a Novel BET Inhibitor with Strong Binding Affinity and Long-lasting Effect in Pre-clinical Models
Started April 18, 2018
422
Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: an Open-label, Phase 1, Dose-escalation, First-in-human Study
Started February 20, 2018
756